hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 04:14:33 - browse：11

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Marvel Studios reveals new trailer for 'The Marvels': Watch here

knowledge

hotspot

WSS

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Republicans love RFK Jr. What's that tell us about health in 2024?

Study: Spinal cord stimulation helps patients with paralysis walk again

Review: 'Barbie' will hit you like a shot in the heart

National associations that represent hospice owe an apology

What to know about Saharan dust affecting the US and how it can affect health

leisure time

hotspot

entertainment

Activists slam private health insurers over coverage restrictions

Abortion policy in the spotlight at Republican debate

Medicare details structure of new drug price negotiation program

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Duchenne breakthrough therapy leaves behind pioneering families

National associations that represent hospice owe an apology

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Intellia plays down concerns on accidental germline transmission

hotspot

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Intellia plays down concerns on accidental germline transmission

Elizabeth Warren probes abortion access

People can get long Covid without testing positive for virus: Study

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Hospital at home shows how to bring innovation to health care

knowledge

hotspot

focus

explore